ZA200805854B - Polymer formulations of CETP inhibitors - Google Patents

Polymer formulations of CETP inhibitors

Info

Publication number
ZA200805854B
ZA200805854B ZA200805854A ZA200805854A ZA200805854B ZA 200805854 B ZA200805854 B ZA 200805854B ZA 200805854 A ZA200805854 A ZA 200805854A ZA 200805854 A ZA200805854 A ZA 200805854A ZA 200805854 B ZA200805854 B ZA 200805854B
Authority
ZA
South Africa
Prior art keywords
cetp inhibitors
polymer formulations
formulations
polymer
cetp
Prior art date
Application number
ZA200805854A
Other languages
English (en)
Inventor
Geers Sarah
Lowinger Michael
Craig A Mckelvey
Robert F Meyer
Zhang Dina
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of ZA200805854B publication Critical patent/ZA200805854B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA200805854A 2006-02-09 2008-07-04 Polymer formulations of CETP inhibitors ZA200805854B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US77178206P 2006-02-09 2006-02-09

Publications (1)

Publication Number Publication Date
ZA200805854B true ZA200805854B (en) 2009-10-28

Family

ID=38198472

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200805854A ZA200805854B (en) 2006-02-09 2008-07-04 Polymer formulations of CETP inhibitors

Country Status (14)

Country Link
US (1) US8030359B2 (https=)
EP (1) EP1983966B1 (https=)
JP (2) JP5773560B2 (https=)
KR (1) KR101418267B1 (https=)
CN (2) CN103735515A (https=)
AU (1) AU2007212197B2 (https=)
BR (1) BRPI0707584A2 (https=)
CA (1) CA2641451C (https=)
IL (1) IL192977A (https=)
NO (1) NO341326B1 (https=)
NZ (1) NZ569700A (https=)
RU (1) RU2457841C2 (https=)
WO (1) WO2007092642A2 (https=)
ZA (1) ZA200805854B (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004085996A2 (en) 2003-03-20 2004-10-07 Albert Einstein College Of Medicine Of Yeshiva University Biomarkers for longevity and disease and uses thereof
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
WO2006073973A2 (en) * 2004-12-31 2006-07-13 Reddy Us Therapeutics, Inc. Novel benzylamine derivatives as cetp inhibitors
AU2008313620A1 (en) * 2007-10-19 2009-04-23 Abbott Gmbh & Co. Kg Solid dispersion product containing N-aryl urea-based compound
JP2011513242A (ja) 2008-02-25 2011-04-28 アミラ ファーマシューティカルズ，インク． プロスタグランジンｄ２受容体アンタゴニスト
AR071375A1 (es) * 2008-04-22 2010-06-16 Solvay Pharm Gmbh Formulaciones para ingredientes farmaceuticos activos de permeabilidad deficiente, proceso de preparacion y producto
AU2011332031B2 (en) 2010-11-24 2017-01-12 Melinta Subsidiary Corp. Pharmaceutical compositions
ES2683350T3 (es) * 2011-07-08 2018-09-26 Novartis Ag Método para tratar la aterosclerosis en sujetos con alto nivel de triglicéridos
US9199967B2 (en) 2011-08-18 2015-12-01 Dr. Reddy's Laboratories Ltd. Substituted heterocyclic amine compounds as cholestryl ester-transfer protein (CETP) inhibitors
MX352074B (es) 2011-09-27 2017-11-08 Dr Reddys Laboratories Ltd Derivados de 5-bencilaminometil-6-aminopirazolo [3,4-b] piridina como inhibidores de proteina de transferencia de ester de colesterilo (cetp) utiles para el tratamiento de aterosclerosis.
MX368859B (es) 2012-05-31 2019-10-18 Merck Sharp & Dohme Formulaciones de dosis solida de un antagonista del receptor de orexina.
KR102160903B1 (ko) * 2012-07-17 2020-10-05 다우 글로벌 테크놀로지스 엘엘씨 고도로 치환된 하이드록시알킬 메틸셀룰로즈를 포함하는 고체 분산물
JP6301339B2 (ja) * 2012-09-27 2018-03-28 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ 少なくとも１種の水溶性ビタミンｅ誘導体および少なくとも１種の親水性ポリマーを含む、保存において安定な無塵の均質な粒子製剤
US20170071930A1 (en) 2012-11-19 2017-03-16 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions of cetp inhibitors
US20160287568A1 (en) * 2013-11-22 2016-10-06 Merck Sharp & Dohme Corp. Composition of a non-nucleoside reverse transcriptase inhibitor
US12168004B2 (en) 2014-02-05 2024-12-17 Merck Sharp & Dohme Llc Treatment of migraine
JP6491669B2 (ja) 2014-02-05 2019-03-27 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｃｇｒｐ活性化合物の錠剤製剤
WO2016084949A1 (ja) * 2014-11-28 2016-06-02 興和株式会社 医薬
JOP20180092A1 (ar) 2017-10-13 2019-04-13 Gilead Sciences Inc مثبطات hiv بروتياز
US12383545B1 (en) 2018-06-08 2025-08-12 Allergan Pharmaceuticals International Limited Treatment of migraine
CN111803632B (zh) * 2019-04-09 2022-04-29 北京五和博澳药业股份有限公司 黄酮多酚类药物自乳化组合物、其制备方法、药物组合物及用途
BR112021020389A2 (pt) * 2019-04-12 2021-12-07 Oblita Therapeutics Bvba Formulações de dosagem em comprimidos de oleil fosfocolina
TW202104210A (zh) 2019-04-17 2021-02-01 美商基利科學股份有限公司 Hiv蛋白酶抑制劑
CN116390712A (zh) 2020-07-29 2023-07-04 阿勒根制药国际有限公司 治疗偏头痛
CA3206184A1 (en) 2020-12-22 2022-06-30 Allergan Pharmaceuticals International Limited Treatment of migraine
WO2023049920A1 (en) 2021-09-27 2023-03-30 Allergan Pharmaceuticals International Limited Combination comprising atogepant for treating migraine

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115279B2 (en) * 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
US6627767B2 (en) 2000-08-29 2003-09-30 Abbott Laboratories Amino(oxo) acetic acid protein tyrosine phosphatase inhibitors
ES2284871T3 (es) 2001-06-22 2007-11-16 Pfizer Products Inc. Composiciones farmaceuticas que contienen una dispersion solida de farmaco poco soluble y un polimero potenciador de la solubilidad.
EP1269994A3 (en) 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
CN100410236C (zh) 2002-01-29 2008-08-13 雪兰诺实验室有限公司 作为蛋白酪氨酸磷酸酶调节剂的取代亚甲基酰胺衍生物
DE60322665D1 (de) * 2002-02-01 2008-09-18 Pfizer Prod Inc Pharmazeutische darreichungsform mit gesteuerter freigabe eines cholesterylester-transferproteininhibitors
PL371593A1 (en) 2002-02-01 2005-06-27 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions using pressure nozzles
BR0306208A (pt) 2002-08-30 2004-10-13 Japan Tobacco Inc Compostos de dibenzilamina e seu uso farmacêutico
MXPA05009848A (es) 2003-03-17 2005-12-06 Japan Tobacco Inc Composiciones farmaceuticas de inhibidores de la proteina de transferencia del ester de colesterilo.
US20070043079A1 (en) 2003-04-18 2007-02-22 Hiromu Habashita Heterocyclic compound containing nitrogen atom and use thereof
DOP2005000123A (es) 2004-07-02 2011-07-15 Merck Sharp & Dohme Inhibidores de cetp
FR2875409B1 (fr) * 2004-09-17 2010-05-07 Sanofi Aventis Composition pharmaceutique comprenant une dispersion solide a matrice polymere comprenant une phase continue de polydextrose et une phase continue d'un polymere autre que du polydextrose
CN102757397A (zh) * 2005-07-01 2012-10-31 默沙东公司 合成cetp抑制剂的方法
EP1965764B1 (en) * 2005-12-05 2011-07-13 Merck Sharp & Dohme Corp. Self-emulsifying formulations of cetp inhibitors

Also Published As

Publication number Publication date
CA2641451C (en) 2012-10-02
WO2007092642A3 (en) 2007-10-04
EP1983966B1 (en) 2013-06-26
IL192977A0 (en) 2009-02-11
JP5648038B2 (ja) 2015-01-07
BRPI0707584A2 (pt) 2011-05-10
CA2641451A1 (en) 2007-08-16
JP2013067635A (ja) 2013-04-18
AU2007212197B2 (en) 2012-12-13
NO341326B1 (no) 2017-10-16
KR101418267B1 (ko) 2014-07-11
KR20080108420A (ko) 2008-12-15
US8030359B2 (en) 2011-10-04
US20100227903A1 (en) 2010-09-09
NO20083821L (no) 2008-09-30
EP1983966A2 (en) 2008-10-29
CN101378731B (zh) 2014-03-05
WO2007092642A2 (en) 2007-08-16
RU2457841C2 (ru) 2012-08-10
RU2008136198A (ru) 2010-03-20
CN101378731A (zh) 2009-03-04
JP5773560B2 (ja) 2015-09-02
IL192977A (en) 2011-01-31
JP2009526075A (ja) 2009-07-16
AU2007212197A1 (en) 2007-08-16
CN103735515A (zh) 2014-04-23
NZ569700A (en) 2011-09-30

Similar Documents

Publication Publication Date Title
ZA200805854B (en) Polymer formulations of CETP inhibitors
ZA200906946B (en) Inhibitors of iap
IL199727A0 (en) Inhibitors of mek
IL195792A0 (en) Amino-piperidine derivatives as cetp inhibitors
EP2026843A4 (en) THERAPEUTIC USES OF RTP801L INHIBITORS
ZA201000318B (en) Inhibitors of 11b-hydroxysteroid dehydrogenase
PT2402319T (pt) Inibidores de dgat
PL2386579T3 (pl) Glioksalowanie polimeru winyloamidu
ZA201000829B (en) Oxadiazole- and oxazole-substituted benzamidazole-and indole-derivatives as dgat1 inhibitors
EP2066687A4 (en) COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF HAMP GENE
ZA201100898B (en) Novel inhibitors
ZA200900927B (en) Glyoxalation of vinylmide polymer
EP2307558A4 (en) COMPOSITIONS AND PROCEDURES FOR THE PROTECTION OF NUCLEOPHILER GROUPS
ZA201102837B (en) Phosphodiestarase inhibitors
GB201114396D0 (en) Location of basesation
GB0604901D0 (en) Improved formulation of COMT inhibitors
IL198149A0 (en) Novel inhibitors of chymase
GB0714941D0 (en) Inhibitors
ZA200810008B (en) Amino-piperidine derivatives as CETP inhibitors
GB0621107D0 (en) Inhibitors of phosphodiesterase-4
EP1997114A4 (en) COMPOSITIONS OF MATERIAL: SYSTEM II
GB0707498D0 (en) Novel inhibitors
GB0707493D0 (en) Novel inhibitors
GB0704589D0 (en) Novel inhibitors
GB0707488D0 (en) Novel inhibitors